Impaired dopamine release and uptake in R6/1 Huntington's disease model mice

Neuroscience Letters

Volumn 492, Issue 1, 2011, Pages 11-14

  Ortiz, Andrea N ^a   Kurth, Benjamin J ^a   Osterhaus, Gregory L ^a   Johnson, Michael A ^a,b  

^a Department of Chemistry   (United States)

^b Neuroscience Program   (United States)

Author keywords

Dopamine; Huntington's disease; R6 1 mice; Release; Uptake; Voltammetry

Indexed keywords

DOPAMINE;

ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; DOPAMINE RELEASE; DOPAMINE UPTAKE; HUNTINGTON CHOREA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; ELECTROCHEMICAL TECHNIQUES; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS;

EID: 79952004099     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.01.036     Document Type: Article

References (14)

1. Bates G.P., Harper P.S., Jones L. Huntington's Disease 2002, Oxford University Press, Oxford, 558 pp.
2. Bolan E.A., Kivell B., Jaligam V., Oz M., Jayanthi L.D., Han Y., Sen N., Urizar E., Gomes I., Devi L.A., Ramamoorthy S., Javitch J.A., Zapata A., Shippenberg T.S. D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Mol. Pharmacol. 2007, 71:1222-1232.
3. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997, 90:537-548.
4. Johnson M.A., Rajan V., Miller C.E., Wightman R.M. Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease. J. Neurochem. 2006, 97:737-746.
5. Kandel E.R., Schwartz J.H., Jessell T.M. Principles of Neural Science 2000, McGraw-Hill, New York.
6. Kraft J.C., Osterhaus G.L., Ortiz A.N., Garris P.A., Johnson M.A. In vivo dopamine release and uptake impairments in rats treated with 3-nitropropionic acid. Neuroscience 2009, 161:940-949.
7. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
8. Mathews C.K., van Holde K.E. Biochemistry 1996, Benjamin/Cummings, Menlo Park, CA, 1158 pp.
9. Ortiz A.N., Kurth B.J., Osterhaus G.L., Johnson M.A. Dysregulation of intracellular dopamine stores revealed in the R6/2 mouse striatum. J. Neurochem. 2010, 112:755-761.
10. Petersén A., Hansson O., Puschban Z., Sapp E., Romero N., Castilho R.F., Sulzer D., Rice M., DiFiglia M., Przedborski S., Brundin P. Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine. Eur. J. Neurosci. 2001, 14:1425-1435.
11. Petersén A., Puschban Z., Lotharius J., NicNiocaill B., Wiekop P., O'Connor W.T., Brundin P. Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice. Neurobiol. Dis. 2002, 11:134-146.
12. Pineda J.R., Canals J.M., Bosch M., Adell A., Mengod G., Artigas F., Ernfors P., Alberch J. Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease. J. Neurochem. 2005, 93:1057-1068.
13. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72(6):971-983.
14. Wu Q., Reith M.E., Wightman R.M., Kawagoe K.T., Garris P.A. Determination of release and uptake parameters from electrically evoked dopamine dynamics measured by real-time voltammetry. J. Neurosci. Methods 2001, 112:119-133.